1. Volume 15, Issue 2, Pages 201-212 (February 2014)
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial 
Dr Helena M Earl, MBBS, Anne-Laure Vallier, MSc, Dr Louise Hiller, PhD, Nicola Fenwick, BSc, Jennie Young, BSc, Mahesh Iddawela, MBBS, Jean Abraham, MBBS, Luke Hughes-Davies, MBBCh, Ioannis Gounaris, MD, Karen McAdam, MBBS, Stephen Houston, MBBS, Tamas Hickish, MBBS, Anthony Skene, MBBS, Stephen Chan, MBBCh, Susan Dean, MBBS, Diana Ritchie, MBBS, Robert Laing, MBBS, Mark Harries, MBBCh, Christopher Gallagher, MBBS, Prof Gordon Wishart, MBBS, Prof Janet Dunn, PhD, Elena Provenzano, MD, Prof Carlos Caldas, MD 
The Lancet Oncology 
Volume 15, Issue 2, Pages (February 2014)
DOI: /S (13)
Copyright © 2014 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

2. Figure 1 Trial profile EC=epirubicin and cyclophosphamide.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

3. Figure 2 Disease-free survival and overall survival from randomisation
(A) Disease-free survival by treatment component. (B) Disease-free survival by treatment sequence. (C) Overall survival by treatment component. (D) Overall survival by treatment sequence EC=epirubicin and cyclophosphamide. HR=hazard ratio. *Adjusted for stratification variables.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

4. Figure 3
Disease-free survival and overall survival from surgery by pathological complete response
(A) Disease-free survival. (B) Overall survival. pCR=pathological complete response. HR=hazard ratio. *Adjusted for stratification variables.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions